Navigation Links
Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
Date:5/15/2008

- Trial Results Confirm Efficacy for Population Most Affected by Disease -

WAYNE, N.J. and EMERYVILLE, Calif., May 16 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that Nexavar(R) (sorafenib) tablets significantly improved overall survival by 47.3 percent (HR=0.68; p-value=0.014) in patients in the Asia-Pacific region with advanced hepatocellular carcinoma (HCC), or primary liver cancer versus those receiving placebo. Nexavar also significantly improved time to progression in these patients by 74 percent (HR=0.57; P=0.001). These data were presented at the 44th annual meeting of the American Society of Clinical Oncology (ASCO) and further confirm Nexavar's efficacy in liver cancer.

The international, Phase 3, randomized trial evaluated efficacy and safety of Nexavar versus placebo in 226 Asian patients with advanced HCC who had not received prior systemic therapy. The study was designed to compare overall survival, time to progression, time to symptomatic progression, response as defined by RECIST criteria and safety in patients receiving Nexavar versus placebo. Median overall survival was 6.5 months in patients treated with Nexavar versus 4.2 months for those taking placebo. The survival benefit was seen across multiple patient subsets analyzed, including age, extrahepatic spread and/or macroscopic vascular invasion.

"Liver cancer in the Asia-Pacific region continues to grow because of a high incidence of chronic hepatitis B viral infections, which now impact approximately 275 million people in the region," said Ann-Lii Cheng, MD, PhD, Department of Internal Medicine and Department of Oncology, National Taiwan University Hospital, Taipei, T
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; OnyxPharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nexavar First FDA-Approved Drug Therapy for Liver Cancer
2. ZymoGenetics Reports Positive Phase 1 Results for IL-21 With Nexavar(R)
3. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
4. Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents
5. Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study
6. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
7. Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome
8. Data Presented at AAN Show That Lacosamide Significantly Reduced Pain and was Generally Well Tolerated in Patients With Diabetic Neuropathic Pain
9. Medivations Dimebon(TM) Significantly Improved Daily Function in Alzheimers Disease Patients, Resulting in Reduced Need for Caregiver Assistance
10. Orqis(R) Medicals Cancion(R) System Significantly Increases Cardiac Performance
11. CV Therapeutics Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 27, 2014  AcelRx Pharmaceuticals, Inc. (Nasdaq: ... development and commercialization of innovative therapies for the treatment ... management will be participating at the FBR Healthcare One ... Global Healthcare Conference.  Details of the two events are ... Conference Date: Wednesday September 3 rd Location: ...
(Date:8/26/2014)...  Kewaunee Scientific Corporation (Nasdaq: KEQU ) ... 31, 2014. Sales for the quarter were ... first quarter last year. Net earnings for the quarter ... to net earnings of $1,587,000, or $0.61 per diluted ... However, both sales and earnings in the first quarter ...
(Date:8/26/2014)... , Aug. 26, 2014  Actavis plc (NYSE: ... that Brenton Saunders , CEO and President of Actavis, ... at the Morgan Stanley Global Healthcare Conference 2014 in ... http://photos.prnewswire.com/prnh/20130124/NY47381LOGO The presentation will take place ... at the Grand Hyatt New York, 109 East 42 nd ...
Breaking Medicine Technology:AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events 2AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events 3Kewaunee Scientific Reports Results for First Quarter 2Kewaunee Scientific Reports Results for First Quarter 3Kewaunee Scientific Reports Results for First Quarter 4Kewaunee Scientific Reports Results for First Quarter 5Kewaunee Scientific Reports Results for First Quarter 6Actavis to Present at Morgan Stanley Global Healthcare Conference 2014 2
... , POTOMAC, Md., Nov. 24 In ... has added Philadelphia jurors to her Thanksgiving gratitude list. ... I am so thankful to them," she said of Monday,s ... , Wisneski is among 12,000 women nationwide who have sued ...
... , , HOLMDEL, ... TrackWise software and the market leader in enterprise quality and ... expanding consumer product company and the parent company for globally ... with TrackWise Enterprise Quality Management System (EQMS). The company is ...
Cached Medicine Technology:Maryland Woman Thankful for Wyeth Verdicts 2SSL International plc Embraces TrackWise(R) Software for Global Quality and Compliance Efforts 2SSL International plc Embraces TrackWise(R) Software for Global Quality and Compliance Efforts 3
(Date:8/27/2014)... 2014 (HealthDay News) -- A new genetic discovery about ... the bowel disorder, researchers report. The scientists ... how their genes work, and said these changes can ... the possibility of a simple diagnostic test for Crohn,s, ... develops and suggest possible gene targets for new treatments, ...
(Date:8/27/2014)... August, 27, 2014) An experimental drug designed to help ... first treatment for anemia of inflammation, according to results from ... online today in Blood , the Journal ... is a condition that occurs when red blood cells are ... individual has anemia, the body does not get enough oxygen, ...
(Date:8/27/2014)... tested an advanced statistical model to evaluate the ... as published yesterday in Human Genetics . ... in current analyses. Complex diseases like cancer usually ... factors. When many such combinations are studied, identifying ... combinations among affected individuals becomes difficult. In this ...
(Date:8/27/2014)... 2014 The Global and China Maleic ... the current state of the Maleic Anhydride industry in ... overview of the industry, including definitions, applications and industry ... analysis are provided with a focus on history, developments, ... between the international and Chinese situation is also offered. ...
(Date:8/27/2014)... Sugar Manufacturing in Australia ... in global supply and demand, which have contributed to ... industry derives a large share of its revenue from ... dynamics, with supply and prices being determined by larger ... Australian dollar for the majority of the past five ...
Breaking Medicine News(10 mins):Health News:Scientists Spot Genetic Clues to Crohn's Disease 2Health News:Drug represents first potential treatment for common anemia 2Health News:Dartmouth isolates environmental influences in genome-wide association studies 2Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 2Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 3Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 4Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 5Health News:Sugar Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Sugar Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Sugar Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 4
... the Staying Sharp session on October 4 at the Embassy ... Part of a highly recognized series, the program will emphasize ... industry; factors that predict future cognitive function; and the importance ... The public can reserve free tickets through the toll-free line: ...
... articulating wall mounted arms that offer a space-saving solution without ... environment. , ... Ferndale, MI (PRWEB) ... the next generation in articulating wall-mounted arms. Offering 270 degrees ...
... Oct. 1 Sysmex America, Inc. and its,subsidiary, ... the,company,s new brand logo, said Kazuya Obe, Executive ... The timing of this brand change,corresponds with the ... and,the company,s 40th anniversary. The new logo marks ...
... with,solutions and recommendations drawing on experience working ... PLYMOUTH MEETING, Pa., Oct. 1 Anticipating,the ... Safety and Quality,Improvement Act of 2005, ECRI ... to improve patient care, will preview its ...
... Researchers at the Farber Institute for Neurosciences ... Psychiatry and Human Behavior at Jefferson Medical College ... $3.7 million grant from The National Eye Institute ... macular degeneration (AMD). Barry W. Rovner, M.D., ...
... Rise of cities, risky behavior in west central Africa between ... 1 (HealthDay News) -- The most pervasive global strain of ... a new study claims. , The research, which is ... that HIV began spreading between 1884 and 1924, around the ...
Cached Medicine News:Health News:Enovate IT Announces Fluid - a New Movement in Wall Arms 2Health News:Sysmex Announces Brand Change 2Health News:ECRI Institute Unveils Comprehensive Patient Safety Organization (PSO) Services 2Health News:ECRI Institute Unveils Comprehensive Patient Safety Organization (PSO) Services 3Health News:Jefferson awarded multi-million dollar grant from National Eye Institute for new clinical trial 2Health News:HIV Outbreak Began Decades Earlier Than Thought 2
TSH EIA Thyroid Function 025-BC-1001...
... The anti-TG test kit is a ... microplate format. It is designed for the ... thyroglobulin (TG) in serum or plasma. The ... 1: Calibrators, controls and patient samples are ...
Free Estriol (E3) RIA Reproductive Hormones 024-IDC-1000...
FSH EIA Reproductive Markers 025-BC-1029 Follicle Stimulating Hormone...
Medicine Products: